Schulz-Knappe
Peter Schulz-Knappe, Hannover DE
Patent application number | Description | Published |
---|---|---|
20080234187 | Human circulating cytokine CC-1 - Cytokine CC-1 having the amino acid sequence according to SEQ ID No. 6 and its biologically active fragments and/or derivatives, in particular amidized, acetylized, phosphorylized and/or glycosylized derivatives. | 09-25-2008 |
Peter Schulz-Knappe, Surrey GB
Patent application number | Description | Published |
---|---|---|
20110111513 | MASS SPECTROMETRIC ANALYSIS - The disclosure provides a method for assaying for a target analyte, comprising providing a plurality of samples which may comprise the target analyte, wherein each sample is differentially labelled with a mass label or a combination of mass labels, wherein the mass labels are from a set of mass labels, wherein each mass label is an isobaric mass label comprising a mass spectrometrically distinct mass marker group, such that the samples can be distinguished by mass spectrometry and determining from the mass spectrum the quantity of the target analyte in each sample. | 05-12-2011 |
Peter Schulz-Knappe, Hemmingen DE
Patent application number | Description | Published |
---|---|---|
20140309133 | Novel Method for Diagnosis of High-Affinity Binders and Marker Sequences - The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterisation and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal. | 10-16-2014 |
20140371095 | NOVEL METHOD FOR IDENTIFYING SPECIFIC MARKER SEQUENCES FOR PROSTATE CANCER - The present invention relates to a novel method for identifying specific marker sequences for diagnosis of prostate cancer and/or for prognosis in prostate cancer, and to the use of the specific marker sequences identified with the aid of this method. | 12-18-2014 |